Abstract
Purpose Three new oral anticoagulants (NOACs) have recently become available in the United Kingdom as an alternative to warfarin in the prevention of stroke and systemic embolism in atrial fibrillation. This study examines the relative cost-effectiveness of dabigatran (BID dosing of 150 mg or 110 mg based on patient age), rivaroxaban, and apixaban from a UK payer perspective.
Author supplied keywords
- United Kingdom
- acetylsalicylic acid
- acute heart infarction
- aged
- apixaban
- article
- aspirin
- atrial fibrillation
- brain hemorrhage
- brain ischemia
- cerebrovascular accident
- controlled study
- cost effectiveness analysis
- dabigatran
- drug cost
- drug efficacy
- female
- follow up
- human
- major clinical study
- male
- quality adjusted life year
- rivaroxaban
- warfarin
Cite
CITATION STYLE
Y., Z., S.V., S., A.-K., G., H., N., J., H.-N., T., S., & A.R., K. (2014). Comparison of the Cost-effectiveness of New Oral Anticoagulants for the Prevention of Stroke and Systemic Embolism in Atrial Fibrillation in a UK Setting. Clinical Therapeutics, 36(12), 2015-2028.e2. Retrieved from http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L600736295
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
